Biotech Archives - Page 711 of 795

1 minute read

Cara Therapeutics Presents Results of Oral Difelikefalin In Painful Itching Disorder

September 8, 2:27 PM

Cara Therapeutics Inc (NASDAQ:CARA) announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for moderate-to-severe pruritus in notalgia…

CARA

1 minute read

Independent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial

By Vandana Singh

September 8, 2:24 PM

Vistagen Therapeutics Inc (NASDAQ:VTGN) completed an interim analysis of PALISADE-2, its second Phase 3 trial assessing drug candidate PH94B as an…

VTGN

1 minute read

Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease

By Vandana Singh

September 8, 1:53 PM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) presented detailed results from the second of two Phase 3 trials (PRIME) evaluating…

REGN

1 minute read

With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium

By Vandana Singh

September 8, 1:50 PM

Cantor Fitzgerald initiated coverage on Actinium Pharmaceuticals Inc (NYSE:ATNM) with an Overweight rating and a price target of $20, almost an upside…

ATNM

1 minute read

Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer

By Vandana Singh

September 8, 1:48 PM

Exelixis Inc (NASDAQ:EXEL) announced detailed results from the COSMIC-313 Phase 3 trial cabozantinib (Cabometyx), nivolumab, and ipilimumab combo in untreated advanced…

EXEL

1 minute read

Gilead’s Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings

By Vandana Singh

September 8, 1:27 PM

Gilead Sciences Inc (NASDAQ:GILD) announced the overall survival (OS) results from the Phase 3 TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) versus…

GILD

1 minute read

Regeneron Highlights Dupixent (dupilumab) Late-Breaking Phase 3 Data At The EADV 2022 Congress; Says Data Show Significant Improvements In Signs And Symptoms Of Prurigo Nodularis

By Benzinga Newsdesk

September 8, 11:30 AM

early three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions at 24 weeks compared to placebo There are currently no approved medicines specifically indicated to treat

REGN

2 minute read

Needham Gives Revance Therapeutics Buy Rating With Note Titled: FDA Approves Daxxify With Anticipated Product Label Differentiation; Raises Price Target From $25 To $35

By Benzinga Newsdesk

September 8, 11:19 AM

https://needham.bluematrix.com/sellside/EmailDocViewer?encrypt=b39360c5-a6d8-49eb-ab7d-06a90478a63f&mim

RVNC

1 minute read

Erasca Touts Promising Early Data From Lead Cancer Programs

By Vandana Singh

September 8, 11:08 AM

Erasca Inc (NASDAQ:ERAS) announced preliminary Phase 1/1b monotherapy data for ERAS-007 and ERAS-601 in solid tumor settings. A retrospective pooled analysis…

ERAS

1 minute read

Alnylam Shares Detailed Patisiran Data From Rare Disease Study

By Vandana Singh

September 8, 10:21 AM

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

ALNY